One Year Later, Mallinckrodt Divestment Options Still Open For Tyco
This article was originally published in The Gray Sheet
Executive Summary
Tyco Healthcare's reluctance to divest its Mallinckrodt subsidiary's pharmaceutical business one year after acquiring the parent company may reflect in part the market potential of partner Palatin Technologies' LeuTech infection imaging agent, for which Mallinckrodt has exclusive marketing and distribution rights.